cology (COT), the COT Subcommittee on the Health Effects of Ingested Fluoride, and the Subcommittee on Pharmacokinetics in Risk Assessment of the Safe Drinking Water Committee. Dr. Krewski chaired the Committee on Acute Exposure Guideline Levels from 1998 to 2004, and the Colloquium on Scientific Advances and the Future of Toxicologic Risk Assessment held in 1997 on the 50th anniversary of the COT. Dr. Krewski received his MSc and PhD in mathematics and statistics from Carleton University and his MHA from the University of Ottawa.
Daniel Acosta, Jr. is dean of the College of Pharmacy at the University of Cincinnati. Dr. Acosta's research focuses on the development of in vitro cellular models to explore and evaluate the mechanisms by which xenobiotics damage cell types. He has worked to develop primary culture systems of liver, heart, kidney, nerve, skin, and eye cells as experimental models to study the cellular and subcellular toxicity of selected xenobiotics. He was president of the Society of Toxicology in 2000-2001 and is editor of Toxicology In Vitro and the Target Organ Series on Cardiovascular Toxicology. Dr. Acosta serves as chair of the Food and Drug Administration Scientific Advisory Board for the National Center for Toxicology Research and was a member of the Board of Scientific Councilors for the Office of Research and Development for the Environmental Protection Agency in 2001-2004. He was a member of the Scientific Advisory Committee to the director of the National Center for Environmental Health of the Centers for Disease Control and Prevention in 2001-2003. He is serving on the Scientific Advisory Committee for Alternative Toxicological Methods for the National Institute of Environmental Health Sciences and the Expert Committee on Toxicology and Biocompatibility for the US Pharmacopoeia (2000-2005). He also served on the National Research Council Howard Hughes Medical Institute Predoctoral Fellowships Panel on Neurosciences and Physiology. Dr. Acosta